

Ref: MHL/Sec&Legal/2026-27/49

October 05, 2026

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Limited
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Code of Fair Disclosure of Unpublished Price Sensitive Information & Policy for Legitimate Purpose in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has provided a business update for the quarter ended September 30, 2026.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended September 30, 2026. A detailed information update will follow once the Board of Directors approves the financial results for Q2FY27.

Consolidated Key Business Highlights of Q2FY27:

1. Revenue grew by approximately **15% on a Y-o-Y** primarily driven by double digit patient & test volume growth, supported by improved realizations and change in product mix.
2. TruHealth Wellness and Specialty segments emerged as the fastest-growing segments during the quarter.
3. EBITDA margins have improved meaningfully on Y-o-Y as well as Q-o-Q basis, driven by operating leverage & efficiency gains.

The quarterly business update is on a consolidated basis. The financial results of Q2FY27 are subject to review by Auditors.

Thanking you,
Yours faithfully,

For Metropolis Healthcare Limited

Kamlesh
Chandrasekhar Kulkarni

Kamlesh C Kulkarni
Head – Legal & Secretarial

